These studies proved apoM could be used as a novel potential marker to evaluate disease activity in chronic obstructive pulmonary disease (COPD) [22] and systemic lupus erythematosus (SLE) [23], and recognized as a critical unfavourable prognostic determinant in COPD and SLE. The gene discussed is APOM; the disease is systemic lupus erythematosus.